What is ivWatch?
ivWatch operates at the intersection of medical device innovation and patient safety, specializing in the development of biosensor technology designed to detect intravenous infiltration and extravasation. By providing real-time, continuous monitoring, the company addresses a persistent challenge in hospital settings where traditional visual assessment often fails to identify complications before tissue damage occurs. As a leader in the biosensor space, ivWatch leverages advanced signal processing to enhance the efficacy of IV therapy, effectively reducing the clinical and financial burden of preventable medical errors. Their market position is fortified by a robust intellectual property portfolio and a clear focus on improving standard-of-care protocols in acute and long-term care facilities.
How much funding has ivWatch raised?
ivWatch has raised a total of $36.9M across 8 funding rounds:
Private Equity
$2.7M
Private Equity
$2.8M
Private Equity
$668K
Private Equity
$12.8M
Private Equity
$14.8M
Private Equity
$2M
Debt
$350K
Debt
$778K
Private Equity (2011): $2.7M, investors not publicly disclosed
Private Equity (2012): $2.8M, investors not publicly disclosed
Private Equity (2014): $668K, investors not publicly disclosed
Private Equity (2015): $12.8M, investors not publicly disclosed
Private Equity (2017): $14.8M, investors not publicly disclosed
Private Equity (2017): $2M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Debt (2021): $778K supported by PPP
Key Investors in ivWatch
Undisclosed Investor
An institutional capital provider specializing in long-term growth equity and medical technology infrastructure.
PPP
Public-Private Partnership
Undisclosed Investor
A private investment firm with a focus on high-impact healthcare innovations and medical device scalability.
What's next for ivWatch?
With the recent infusion of $778K, ivWatch is well-positioned to accelerate its commercial expansion and deepen its penetration into the global healthcare market. The strategic roadmap likely involves scaling manufacturing capabilities to meet rising demand for its monitoring systems and investing in clinical research to further validate the long-term outcomes of its technology. As the company transitions into this next phase of growth, the focus will remain on integrating its biosensor platforms into standard hospital workflows, thereby cementing its status as an essential component of modern intravenous care. Future initiatives will likely prioritize the development of next-generation sensors and the expansion of its digital health ecosystem to provide clinicians with actionable, data-driven insights.
See full ivWatch company page
